Prostatic Acid Phosphatase (PAP): Prostate Cancer Marker, Meaning & Results

Sample type: Serum

Other names: Acid Phosphatase, Prostatic, Prostatic Acid Phos.

Optimal result: 0 – 3.5 ng/mL

What does it mean if Prostatic Acid Phosphatase is high?

Elevated PAP levels may indicate:

  • Advanced or metastatic prostate cancer
  • Progression of known prostate malignancy
  • Poorer prognosis in prostate cancer patients
  • In rare cases, other conditions affecting prostate tissue

Symptoms that may be associated (if due to prostate cancer):

  • Difficulty urinating or weak urine flow
  • Bone pain (suggesting metastasis)
  • Pelvic discomfort
  • Unexplained weight loss (advanced stages)

What to do next:

  • Compare with Prostate-Specific Antigen levels
  • Review imaging (MRI, bone scan) if clinically indicated
  • Discuss oncology referral if not already under care
  • Track trends over time (using consistent assay method)

Prostatic Acid Phosphatase (PAP) is an enzyme produced by prostate cells and historically used as a tumor marker for prostate cancer, particularly advanced or metastatic disease. While largely replaced by Prostate-Specific Antigen testing for screening, PAP remains clinically relevant in specific cases. It is often used alongside PSA to provide additional insight into disease progression, prognosis, and response to therapy, especially when PSA results are inconclusive.

Prostatic Acid Phosphatase (PAP) is a glycoprotein enzyme secreted by the prostate gland. It was one of the earliest biomarkers used in the detection and monitoring of prostate cancer, particularly after the association between elevated PAP levels and metastatic prostate cancer was identified in the 1930s.

Today, PAP is primarily used as an adjunct marker rather than a primary screening tool. It is most valuable in assessing advanced prostate cancer, monitoring treatment response, and providing prognostic information when used alongside Prostate-Specific Antigen. In some cases, PAP may be elevated even when PSA levels are normal, helping identify specific disease subtypes or progression patterns.

Compared to PSA, PAP is considered more specific but less sensitive. This means it produces fewer false positives (for example, from benign prostate enlargement), but may miss early-stage disease. Elevated PAP levels are more strongly associated with prostate cancer that has spread beyond the prostate (metastatic disease), making it particularly useful in staging and monitoring.

Clinically, PAP may be ordered in the following contexts:

  • Evaluation of suspected advanced prostate cancer
  • Monitoring response to prostate cancer treatment
  • Assessing disease progression or recurrence
  • Complementing PSA testing when results are unclear

Because different laboratory methods can produce varying results, it is important that PAP levels are monitored consistently using the same assay when used for follow-up.

Clinical Notes / Nuances

  • PAP is not interchangeable across assays—use the same lab method for monitoring
  • More specific than PSA but less sensitive for early detection
  • Particularly useful in PSA-negative prostate cancer cases
  • Requires proper handling (frozen serum) to ensure accuracy
Prostatic Acid Phosphatase (PAP)
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Prostatic Acid Phosphatase (PAP) — 10,000+ markers explained
One Prostatic Acid Phosphatase (PAP) result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

  1. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer
    Killian CS, Emrich LJ, Vargas FP, Yang N, Wang MC, Priore RL, Murphy GP, Chu TM. · 1986 View source ↗
Article Review Log
Last reviewed April 10, 2026
Originally published April 10, 2026
Reviewed by HealthMatters Editorial Team
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro